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This research work aimed at determining the UVA effectiveness (UVA I/UV ratio), by diffuse transmittance analysis, of sunscreens 
developed with a bioactive substance, the rutin, associating or not with organic UVB-UVA filters incorporated at a phosphate-base 
O/W emulsion. Sunscreens provided conflicting and unpredictable results concerning the anti-UVA protection, specially, at the 
UVA I region. Possible interactions among the organic UV filters and the polyphenolic bioactive substance may have accounted 
with improvement or reduction of UV protection by a complex and not yet elucidated mechanism, probably regarding wavelength 
delocalization to superior or inferior values, by resonant molecule stabilization or destabilization.
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INTRODUCTION
The knowledge of the effects of UVB and UVA radiation on 
human skin has increased significantly1,2 and the authentic necessity 
of human skin protection against solar radiation has led to the concer-
ning and upgrading of the development of broad spectrum sunscreens 
highly effectives over the UVB-UVA absorbing range. 
Sunscreens are mainly used to prevent erythema formation from sun 
exposure and solar radiation at the Earth’s surface is approximately 90-
99% UVA and 1-10% UVB.3,4 UVB (290-320 nm) radiation primarily 
causes photocarcinogenesis due its direct interaction with cellular DNA 
but there are several reasons why investigation of the role of UVA is also 
relevant. Major consequence of cumulative UVA (320-400 nm) radiation 
is the generation of reactive oxygen species and the alteration of tumor 
suppressor genes, like p53. UVA radiation is additional subdivided into 
UVA II (320-340 nm) and UVA I (340-400 nm).2,5,6
UVA radiation directly affects the dermal compartment and is 
thought to be the major factor responsible for photoaging of human 
skin. It had been shown that the UVA I accounts for damaging effects 
in human dermal fibroblasts, as induction of cytokines, matrix me-
talloproteinases, and mtDNA mutations. Of these, the induction of 
matrix metalloproteinase-1 which degrades collagen type I is of par-
ticular significance since the extent of collagen I reduction correlates 
with photodamage in skin.6,7
This research work aimed at determining the in vitro UVA effecti-
veness of sunscreens developed with a bioactive substance, the rutin, 
associating or not with organic UVB-UVA filters incorporated at a 
phosphate-base O/W emulsion. Mainly, UVA effectiveness was ob-
tained by the UVA I/UV ratio with diffuse transmittance analysis. 
EXPERIMENTAL 
Isolated rutin (99.1%, Henrifarma, Brazil), ethylhexyl methoxy-
cinnamate (EHMC) (UVB organic filter, Uvinul® MC 80, Basf, Brazil) 
and benzophenone-3 (BZP) (UVA organic filter, Uvinul® M 40, Basf, 
Brazil) were incorporated into emulsified systems in accordance with 
the following associations: CB – no active substances; CR – 0.1% w/w 
rutin; CMF – 3.5% w/w EHMC + 1.0% w/w BZP; CMFR – 0.1% w/w 
rutin + 3.5% w/w EHMC + 1.0% w/w BZP; CF – 7.0% w/w EHMC 
+ 2.0% w/w BZP; and CFR – 0.1% w/w rutin + 7.0% w/w EHMC + 
2.0% w/w BZP. 
Emulsified system was previously developed by Velasco and 
co-workers8 as a phosphate-base O/W emulsion, containing: cetearyl 
alcohol (and) dicetyl phosphate (and) ceteth-10 phosphate (Croda-
fos® CES); disodium EDTA (Uniquelan® NA2S); dimethicone (DC® 
200/350); propylene glycol; paraben-type preservatives (Phenova®) 
and aqua (distilied water).
Absorbance spectra of the samples were measured by diffuse 
transmittance analysis (UV1000S Ultraviolet Transmittance Analyzer 
coupling to an integrating sphere, Labsphere®) in 5 nm increments 
from 290 to 400 nm. Prior to the UVA I effectiveness assessment, the 
substrate (Vitro-Skin®) composed of collagen was hydrated (24 h) 
and, then, 70.0 mg of the samples were homogeneously spread over 
it with circular movements, edges to center, by a saturated gloved 
finger. Samples were allowed to rest and to dry at room temperature 
until absorbance recording.9-11
UVA I/UV ratio was calculated according to the following equa-
tions, as described by US Food and Drug Administration:11
aUVA I/λ = 5/3 x [A290 + A400 + 4(A345 + … + A395) + 2(A350 
+ A360 + … +A390)]/60  (1)
UVA I area per unit wavelength (aUVA I/λ). A: absorbance.
aUV/λ = 5/3 x [A290 + A400 + 4(A295 + A305 + A315 + … + A395) 
+ 2(A300 + A310 + … +A390)]/110  (2)
UV area per unit wavelength (aUV/λ). A: absorbance.
 (3)
UVA I/UV ratio.
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RESULTS AND DISCUSSION
Bioactive compounds, such as isolated rutin, are an increasing 
trend toward to the development of suncare cosmetic products, like 
sunscreens, effectively active against UV radiation that are composed 
of decreasing organic UV filter proportions and, yet, appreciating 
high absorbing properties ranging from UVB to UVA. 
Highest values of UVA I/UV ratio were obtained for CB (1.37) 
and CR (1.59). Table 1 summarizes the UVA I/UV ratios. Rutin alone 
at the emulsified system and the vehicle active-free reached values in 
the order of 2 times superior than the systems containing the other 
associations of the bioactive compound and the organic UV filters 
(CMF, CMFR, CF and CFR). 
Organic UV filters, from CMF and CF, acquired UVA I/UV ratios 
of 0.73 and 0.79, respectively. These sunscreens differentiated from 
each other by the proportions of EHMC and BZP. It was observed 
that these organic UV filter associations were not as effective against 
UVA I as CB and CF. It was also verified that the 2-fold increase 
in UV-filter proportion did not promote augmentation of the UVA I 
protection, nevertheless, as demonstrated by Velasco and co-workers,8 
there has been the enhancement of the UVB protection effectiveness, 
by in vitro sun protection factor (SPF) estimation, of 7.34 + 0.24 
(CMF) to 14.63 + 2.05 (CF). 
Couteau and co-workers10 and El-Boury and co-workers12 esta-
blished that SPF is a function of UV filter concentration, which we 
have previous observed8 and, consistent with our results, we have 
noticed that the elevation of the UV filter proportion in a sunscreen 
did not intrinsically provide the respective improvement of the UVA 
protection. Furthermore, the bioactive association with the organic UV 
filters decreased the rutin UVA I defense in which CMFR and CFR 
generated equal UVA I/UV ratio values of 0.84. This observation was 
not expected to CMFR since the presence of 0.1% w/w rutin enhanced 
the SPF of 7.34 + 0.24 to (CMF) to 9.97 + 0.18 (no SPF improvement 
was achieved when rutin was associated 7.0% w/w EHMC + 3.0% w/w 
BZP). This phenomenon might be attributed to an electron stabilization-
destabilization mechanism of the UV filter molecules (resonant struc-
tures) due to the presence of polyphenolic compound (rutin) in which 
the UV filter concentration appeared to be a critical factor.13-15
Parameters and categories that are employed to classify the UVA 
effectiveness11 were reported in Tables 2 and 3. Among them, it is 
currently used the UVA rating, critical wavelength (λ
c
, nm) and, 
more recently, UVA I/UV ratio. US Food and Drug Administra-
tion1,11 categorized each one of them and in Table 3 we used these 
categories to classify the sunscreen emulsified systems presented 
wherein with the addition of previous results.8 All sunscreens 
and the vehicle active-free were of, at least, high UVA protection 
according to UVA I/UV ratio and λ
c
. Regarding the UVA rating, 
systems were of medium (CMF, CMFR, CF and CFR) to high (CB 
and CR) anti-UVA defensives. 
CONCLUSIONS
In summary, sunscreen emulsified systems containing bioactive 
compounds provided conflicting and unpredictable results, through 
in vitro assessment, concerning the anti-UVA protection, specially, 
at the UVA I region. Possible interactions among the organic UV 
filters and the polyphenolic bioactive substance may have accounted 
with the improvement or reduction of UV protection by a complex 
and not yet elucidated mechanism, probably regarding wavelength 
delocalization to superior or inferior values, by resonant molecule 
stabilization or destabilization. 
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Table 1. UVA I/UV ratio values for the sunscreen emulsified systems 
(n = 5)
CB CR CMF CMFR CF CFR
aUVA I 0.05 0.15 0.42 0.54 0.71 0.71
aUV 0.04 0.10 0.57 0.68 0.84 0.84
UVA I/UV ratio 1.37 1.59 0.73 0.79 0.84 0.84
CB – no active substances; CR – 0.1% w/w rutin; CMF – 3.5% w/w 
EHMC + 1.0% w/w BZP; CMFR – 0.1% w/w rutin + 3.5% w/w 
EHMC + 1.0% w/w BZP; CF – 7.0% w/w EHMC + 2.0% w/w BZP; 
CFR – 0.1% w/w rutin + 7.0% w/w EHMC + 2.0% w/w BZP
Table 2. Categories of anti-UVA effectiveness in reference to US Food 
and Drug Administration, with some modification, based on UVA I/
UV ratio, critical wavelength (λ
c
, nm) and UVA rating11
Low Medium High Highest 
UVA I/ 
UV ratio 0.20 to 0.39 0.40 to 0.69 0.70 to 0.95
greater than 
0.95
λ
c
 (nm) 325 to 335 335 to 350 350 to 370 greater than 370
UVA rating 0.20 to 0.39 0.40 to 0.69 0.70 to 0.95 greater than 0.95
Table 3. Anti-UVA categories of the sunscreen emulsified systems: UVA I/UV ratio, critical wavelength (λ
c
, nm) and UVA rating (n = 5) 8,11
CB CR CMF CMFR CF CFR
UVA I/UV ratio  
Category of UVA protection 
1.37  
Highest
1.59  
Highest
0.73  
High
0.79  
High
0.84 
High
0.84  
High
λ
c
 (nm)* 
Category of UVA protection 
386  
Highest
385  
Highest
359  
High
363  
High
361  
High
363  
High 
UVA rating*  
Category of UVA protection 
0.77  
High
0.95  
High to highest
0.44  
Medium
0.46  
Medium
0.49  
Medium 
0.50  
Medium
CB – no active substances; CR – 0.1% w/w rutin; CMF – 3.5% w/w EHMC + 1.0% w/w BZP; CMFR – 0.1% w/w rutin + 3.5% w/w EHMC 
+ 1.0% w/w BZP; CF – 7.0% w/w EHMC + 2.0% w/w BZP; CFR – 0.1% w/w rutin + 7.0% w/w EHMC + 2.0% w/w BZP; (*): Velasco and 
co-workers (2008) 8
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